文献速递胸部肿瘤

ALK阳性非小细胞肺癌进展后继续使用劳拉替尼的临床获益分析

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
PubMed 文献 · J Thorac Oncol · 2022-01-10

该研究基于正在进行的2期试验(NCT01970865)进行回顾性分析,探讨ALK阳性NSCLC患者进展后继续使用劳拉替尼(LBPD)的临床获益。A组(既往仅克唑替尼,n=28)和B组(既往至少一种二代ALK TKI,n=74)中,继续LBPD患者的中位治疗持续时间分别为32.4个月和16.4个月,而未继续者分别为12.5个月和7.7个月。结论认为,对于经选择的劳拉替尼进展后ALK阳性NSCLC患者,继续LBPD是可行的治疗策略。

要点

  • A组继续LBPD中位治疗持续时间32.4个月,未继续者12.5个月。
  • B组继续LBPD中位治疗持续时间16.4个月,未继续者7.7个月。
  • A组继续LBPD中位OS未达到,未继续者24.4个月(95%CI 12.1-NR)。

核心结论

  • 对于经选择的劳拉替尼进展后ALK阳性NSCLC患者,继续LBPD是可行的治疗策略。

研究设计与样本

  • 正在进行的2期试验(NCT01970865)的回顾性分析,评估进展后继续劳拉替尼(LBPD)的临床获益。
  • A组为既往仅接受克唑替尼治疗的患者(n=28),B组为既往至少接受一种二代ALK TKI治疗的患者(n=74)。
  • LBPD定义为研究者评估疾病进展后继续劳拉替尼治疗超过3周。
  • 仅纳入最佳总体疗效为完全缓解、部分缓解或疾病稳定的患者。

主要发现

  • 两组基线特征无重大差异。
  • 继续LBPD患者的中位治疗持续时间:A组32.4个月,B组16.4个月;未继续LBPD患者分别为12.5个月和7.7个月。
  • A组继续LBPD患者中位总生存未达到(NR),未继续LBPD患者为24.4个月(95%CI 12.1-NR)。
  • B组继续LBPD患者中位总生存为26.5个月(95%CI 18.7-35.5),未继续LBPD患者为14.7个月(95%CI 9.3-38.5)。
  • 进展后中位总生存:继续LBPD患者中A组NR(95%CI 21.4-NR),B组14.6个月(95%CI 11.2-19.2);未继续LBPD患者中A组8.0个月(95%CI 1.5-NR),B组5.3个月(95%CI 2.8-14.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lorlatinib, a potent, selective third-generation ALK tyrosine kinase inhibitor (TKI), exhibited overall and intracranial antitumor activity in patients with ALK-positive NSCLC. METHODS: Retrospective analyses in the ongoing phase 2 trial (NCT01970865) investigated the clinical benefit of continuing lorlatinib beyond progressive disease (LBPD). Patients with previous crizotinib treatment as the only ALK TKI were group A (n = 28); those with at least one previous second-generation ALK TKIs were group B (n = 74). LBPD was defined as greater than 3 weeks of lorlatinib treatment after investigator-assessed progressive disease. Only patients with the best overall response of complete or partial response or stable disease were included. RESULTS: There were no major differences in baseline characteristics between groups. The median duration of treatment for patients who continued LBPD was 32.4 months (group A) and 16.4 months (group B) versus 12.5 months (group A) and 7.7 months (group B) for patients who did not continue LBPD. The median overall survival in group A was not reached (NR) in patients who continued LBPD versus 24.4 months (95% confidence interval [CI]: 12.1-NR); group B's median was 26.5 months (95% CI: 18.7-35.5) in patients who continued LBPD versus 14.7 months (95% CI: 9.3-38.5) in patients who did not continue LBPD. The median overall survival postprogression for groups A and B was NR (95% CI: 21.4-NR) and 14.6 months (95% CI: 11.2-19.2) in patients who continued LBPD and 8.0 months (95% CI: 1.5-NR) versus 5.3 months (95% CI: 2.8-14.3) in patients who did not continue LBPD. CONCLUSIONS: Continuing LBPD is a viable treatment strategy for select patients with ALK-positive NSCLC who progressed on lorlatinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ou SI, Solomon BJ, Shaw AT, et al. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. J Thorac Oncol. 2022. PMID: 35026476. doi:10.1016/j.jtho.2021.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。